Requirements to test new drugs against older medicines would add a major hurdle to the development and approval of new medicines. Equally important, the proposed mandates are unnecessary.

Adding a new mandatory "comparative effectiveness" test to the approval process for new drugs in the reauthorization of the Food and Drug Administration (FDA) Prescription Drug User Fee Act constitutes a needless waste of time and money.

At this AEI event, experts discussed whether CER is likely to reduce costs without sacrificing the quality of care.

This paper analyses the impact of comparative effectiveness research (CER) on health and medical care spending interpreting CER to shift the demand for some treatments at the expense of others.

If a new comparative effectiveness research agency is allowed to use different--or inferior--scientific standards than those imposed on the private sector, the government will be the only voice in CER.

Does increased use of technology in itself cause more rapid growth in US health care expenditures as a share of the economy, compared to other countries?

The "bloody crossroads" of science and policy will be the subject of an all-day discussion at AEI.